Drug Profile
Apararenone - Mitsubishi Tanabe Pharma
Alternative Names: MT-3995Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Amides; Antihyperglycaemics; Antihypertensives; Benzoxazines; Hepatoprotectants; Small molecules
- Mechanism of Action Aldosterone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic nephropathies; Hypertension; Non-alcoholic steatohepatitis
Most Recent Events
- 26 Jul 2021 Discontinued - Phase-I for Diabetic nephropathies (In volunteers) in United Kingdom, by July 2021 (PO) (Mitsubishi Tanabe Pharma Corporation pipeline, August 2021)
- 26 Jul 2021 Discontinued - Phase-I for Diabetic nephropathies in USA, by July 2021 (PO) (Mitsubishi Tanabe Pharma Corporation pipeline, August 2021)
- 26 Jul 2021 Discontinued - Phase-II for Diabetic nephropathies in Japan, Hungary, Lithuania, Slovakia, Czech Republic, Bulgaria, Romania, Poland, by July 2021 (PO) (Mitsubishi Tanabe Pharma Corporation pipeline, August 2021)